Goodbody Health Inc. (“Goodbody” or “Goodbody Health” the “Company” or the “Group”) 23rd August 2022 Goodbody Health Provides Shareholders Update on Completion of Continuation Goodbody
Goodbody Health Inc. (“Goodbody” or “Goodbody Health” the “Company” or the “Group”) 19th August 2022 Goodbody Health Inc publishes half year financial results Q2 2022
Goodbody Health Inc. (“Goodbody” or “Goodbody Health” the “Company” or the “Group”) 10th August 2022 Goodbody Health ProvidesAnnual General and Special Meeting of Shareholders Update
Goodbody Health Inc. (“Goodbody” or “Goodbody Health” the “Company” or the “Group”) 14th July 2022 Goodbody Health announces Annual General and Special Meeting of Shareholders
Goodbody Health (AQSE: GDBY) is pleased to announce that it is launching new genetic cancer tests to help customers gauge and understand their cancer and heart disease risk better in conjunction with Everything Genetic.
Goodbody Health (AQSE: GDBY) is pleased to announce that following its application for registration with the Care Quality Commission (CQC) last year, the Company has successfully passed the registration criteria and now provides all its testing services under the regulated activity diagnostic and screening procedures. CQC is the independent regulator of health and adult social care in England.
Goodbody Health (AQSE: GDBY) today announces its intention to de-list from the Canadian Securities Exchange (“CSE”) and to re-domicile the Company from the Province of British Columbia to Guernsey, subject to shareholder approval. This re-domiciliation is intended to better align Goodbody’s corporate structure with its current and future business activities.
Goodbody Health (AQSE: GDBY) is pleased to announce that it has launched its core UK Health “MOT” test which offers a comprehensive summary of a person’s health. Keenly priced at £99, this new test includes innovative in-clinic diabetes and cholesterol tests, with results finalised in minutes.
Goodbody Health Inc. is pleased to announce its highest comprehensive profit of £0.10m and adjusted EBITDA of £0.23m in its unaudited Interim Financial Statements for the three months to 31 March 2022. The revenue at £5.17m was also the second-best quarter to date after Q4 2021.
Goodbody Health Inc. is pleased to announce today a positive adjusted EBITDA of £0.48 million in its audited Financial Statements for the year to 31 December 2021. The Company has filed the Financial Statements and Management’s Discussion and Analysis for year ending 2021 with strong results, especially in the second half of the year due to its growth in testing services. All amounts unless stated otherwise are presented in British Pounds (GBP).
Goodbody Health (AQSE: GDBY) is pleased to announce that its subsidiary, PhytoVista Laboratories, has been granted a controlled drugs licence that allows the company to handle up to Schedule 1 Controlled Drugs. This comes as the UK authorities look to the regulation of the UK consumer cannabinoid product testing infrastructure ahead of wider compliance within the industry.
Goodbody Health (AQSE: GDBY) is pleased to announce that, following the UK Food Standard Agencies (FSA) publication of the Novel Foods approved list for CBD, the Company’s application has been authorised by the FSA to the next stage of the Novel Foods submission, being the publication of the Awaiting Evidence List. This means the FSA are now awaiting the final toxicology results and are satisfied with all the other evidence submitted. Once received, and if successful, the Company will progress onto the final Validated list.